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The organic anion transporting polypeptides (OATPs) encompass a family of membrane transport proteins responsible for the
uptake of xenobiotic compounds. Human organic anion transporting polypeptide 1B1 (OATP1B1) mediates the uptake of clinically
relevant compounds such as statins and chemotherapeutic agents into hepatocytes, playing an important role in drug delivery and
detoxification.TheOATPs have a putative 12-transmembrane domain topology and a highly conserved signature sequence (human
OATP1B1: DSRWVGAWWLNFL), spanning the extracellular loop 3/TM6 boundary. The presence of three conserved tryptophan
residues at the TM interface suggests a structural role for the sequence.Thiswas investigated by site-directedmutagenesis of selected
amino acids within the sequence D251E, W254F, W258/259F, and N261A. Transport was measured using the substrate estrone-3-
sulfate and surface expression detected by luminometry and confocal microscopy, facilitated by an extracellular FLAG epitope.
Uptake of estrone-3-sulfate and the surface expression of D251E, W254F, and W258/259F were both significantly reduced from
the wild type OATP1B1-FLAG in transfected HEK293T cells. Confocal microscopy revealed that protein was produced but was
retained intracellularly. The uptake and expression of N261A were not significantly different. The reduction in surface expression
and intracellular protein retention indicates a structural and/or membrane localization role for these signature sequence residues
in the human drug transporter OATP1B1.
1. Introduction
The organic anion transporting polypeptides (OATPs) are a
family of membrane transport proteins capable of transport-
ing an array of structurally diverse endogenous and xeno-
biotic compounds [1–3]. The proteins are expressed in a
variety of tissues, including absorptive/excretory cells of the
liver and kidney, acting as both a drug delivery and a drug
detoxification system.
The human organic anion transporting polypeptide
1B1 (OATP1B1) (gene symbol SLCO1B1, previously OATP2,
OATP-C, and LST-1) [4] is expressed solely on the basolateral
membrane of hepatocytes, facilitating the uptake of clinically
relevant compounds such as antibacterial drugs, statins, and
chemotherapeutic drugs [5]. As well as playing an important
role in hepatic drug disposition [6], OATP1B1 also acts as
an active drug delivery system for statins to the liver as a
target organ [7]. The protein has been implicated in many
drug-drug interactions, including those with cyclosporine
A, rifampicin, and statins [8–10]. Many individual DNA
nucleotide changes known as single nucleotide polymor-
phisms (SNPs) have also been located inOATP1B1, contribut-
ing to changes in the absorption, distribution, metabolism,
and excretion (ADME) of compounds [5, 11]. Finally, studies
have shown that in tumour tissues the normal liver specific
OATP1B1 is highly expressed [12, 13], suggesting that this
transporter may be a suitable target for tumour immunother-
apy [12].Therefore knowledge of the structure and function of
this transporter is imperative to understand how the delivery
of xenobiotic compounds occurs.
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Table 1: The human OATPs with each signature sequence region. OATP1B1 amino acids mutated during this study are bold and underlined.
Source: NCBI [18].
OATP Signature sequence
OATP1A2 D T R W V G A W W F G F L
OATP1B1 D S R W V G A W W L N F L
OATP1B3 D S R W V G A W W L G F L
OATP1C1 D P Q W V G A W W L G Y L
OATP2A1 D P R W I G A W W L G L L
OATP2B1 D P R W V G A W W L G F L
OATP3A1 D P R W I G A W W G G F L
OATP4A1 S P L W V G A W W V G F L
OATP4C1 D P R W L G A W W I G F L
OATP5A1 D P R F I G N W W S G F L
OATP6A1 S P E W L W T W W I N F L
OATP1B1 has been previously predicted by topology
prediction analyses to contain 12 transmembrane domains
(TMs) and intracellular amino (N) and carboxyl (C) termini
[2, 14]. Meier-Abt et al. modeled OATP1B3 on the major
facilitator superfamily transporters, glycerol-3-phosphate
(GlpT) and lactose permease [15], also predicting the 12-TM
topology. Experimental analyses with epitope tagging have
inferred that rat OATP1A1 has 12 TMs and confirmed that the
C-terminus of OATP1B1 is located intracellularly [16, 17].
The OATPs are also characterized by a conserved 13
amino acid signature sequence (D-X-RW-(I,V)-GAWW-XG-
(F,L)-L) (Table 1) at the border between the extracellular
loop 3 and TM 6. The position of this sequence at the
TM interface, combined with the presence of three highly
conserved tryptophan residues, suggests a potential role in
stabilizing the protein within the membrane [19, 20]. To date,
only the portion of the sequence predicted to encompass
TM6 has been studied (A257, W258, W259, L260, N261,
F262, and L263) [21, 22]. Mutation of W258, W259, and
F262 to alanine in OATP1B1 showed a significant decrease
in transport, suggesting a role in protein function [21]. The
remaining mutants were unaffected.
Tryptophan could be an important amino acid for deter-
mining the structure of a transmembrane protein owing to
its nonpolar surface area, the capability for hydrogen bond
formation, and a high electrostatic potential [23]. Individ-
ual mutation of tryptophans W258 and W259 in human
OATP1B1 to alanine however had differing effects on the
transport of different substrates, but surface expression was
unaffected [21]. In contrast, when the equivalent tryptophans
were mutated individually and as a double mutant to pheny-
lalanine in rat OATP1C1, protein function was preserved
[21, 22].
In this study, the topology of OATP1B1 was predicted
using homology modelling software and the consensus of
10 topology prediction programs. These results were used to
predict the position of the TMs and the signature sequence.
The programs predicted a 12-TM protein with the signature
sequence spanning the extracellular loop 3 and TM 6. These
results were then used to place a FLAG epitope into the
extracellular loop 2 of OATP1B1, for the detection of protein
on the membrane.
The function of the OATP1B1 signature sequence was
investigated by site-directed mutagenesis of the most con-
served amino acids within the sequence D251, W254,
W258/W259, and N261A (Table 1). This included those pre-
dicted within extracellular loop 3, D251, and W254, which
have not been previously studied. Conservative mutations
weremade to the chosen amino acids to assess the importance
of the amino acid for protein function. Therefore, the polar
aspartic acid was mutated to glutamic acid (D251E), both
being negatively charged polar residues.Thenonpolar trypto-
phans W254 and W258/259 were mutated to the structurally
similar and aromatic phenylalanine (W254F andW258/259F,
resp.). In addition, asparagine 261 (N261) in the OATP1B1
sequence is not conserved among the vast majority of the
other OATPs, where this residue is a nonpolar glycine.
Therefore N261 was mutated to alanine to investigate the role
of this amino acid in the sequence.
Transport function by OATP1B1 was measured using the
radiolabelled substrate [3H]estrone-3-sulfate ([3H]E3S) and
surface expression was detected via the FLAG epitope in
HEK293T cells using luminometry, a quantitative chemi-
luminescence method, and confocal microscopy following
immunofluorescence. Results revealed a significant reduc-
tion in surface expression and transport for the D251E,
W254F, and W258/259F signature sequence mutants, with
confocal microscopy revealing the protein to be retained
intracellularly. N261A transport and surface expression were
comparable to the wild type.
2. Materials and Methods
2.1. Materials. Radiolabeled [3H]estrone-3-sulfate ([3H]E3S)
(54.3 Ci/mmol) was purchased from Perkin Elmer (MA,
USA). All other chemicals including the anti-FLAG antibod-
ies were purchased from Sigma Aldrich (Dorset, UK), unless
stated otherwise.
2.2. Topology Prediction. The topology of OATP1B1 was
predicted using the online prediction programs TOPCONS
[24], Phobius [25], TMpred [26], TopPred II [27], Membrain
[28], PHDhtm [29], Split 4.0 [30], Philius [31], HMMTOP
[32], SVMtm [33], ConPred II [34], SOSUI [35], TMHMM
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[36], TSeg [37], PRED-TMR [38], and MEMSAT3 [39]. A
homology model was generated using the Protein Homol-
ogy/analogY Recognition Engine V 2.0 (PHYRE2) [40],
which modeled the OATP1B1 sequence on the known struc-
ture of GlpT [41].
2.3. Cloning and Mutagenesis. The SLCO1B1 gene was cloned
into the mammalian vector pcDNA3.1/Hygro(-) (Life Tech-
nologies Ltd., Paisley, UK) with XhoI and KpnI. An overlap
extension PCR method [42] was used to insert the 24-
base DNA sequence for the FLAG epitope (DYKDDDDK)
into the putative extracellular loop between TMs 3 and 4
(termedOATP1B1-FLAG).The signature sequencemutations
were made using overlap extension site-directed mutagene-
sis of the extracellularly tagged OATP1B1-FLAG construct,
which was then used as the wild type. All cloning and
mutagenesis were confirmed by DNA sequencing. FLAG
primers were as follows: OATP1B1 N-term, 5󸀠-ttttttctcgag-
gccaccatggaccaaaatcaac-3󸀠; OATP1B1 C-term, 3󸀠-aaaaaa-
ggtacctcccttaacaatgtgtttc-5󸀠; OATP1B1-FLAG, 5󸀠-caacatcaa-
ccttatccactgattataaggacgacgacgacaagtgtttaattaatcaaattttatc-
3󸀠 (complementary). Complementary forward primers for
the signature sequence mutants were as follows: D251E,
5󸀠-ggataactcctactgagtctcgatgggttgg-3󸀠; W254F, 5󸀠-ctactg-
attctaaatttgttggagcttggtgg-3󸀠; W258/259F, 5󸀠-cgatgggttgga-
gctttcttccttaatttccttgtg-3󸀠; N261A, 5󸀠-ttggagcttggtggcttgctttc-
cttgtgtctggactattctc-3󸀠.
2.4. Protein Expression in HEK293T Cells. Human embry-
onic kidney 293T (HEK293T (ATCC, Manassas, VA)) cells
were grown at 37∘C with 5% CO
2
in Dulbecco’s modified
eagles medium, supplemented with 10% FBS (Life Technolo-
gies, Paisley, UK), 1X penicillin-streptomycin, 250 𝜇g/mL
amphotericin-B, 2mM L-glutamine, and 1X nonessential
amino acids solution. Cells at ∼80% confluence were har-
vested using 1X accutase solution (Millipore, Watford, UK)
and transfected with the Amaxa Cell Line Nucleofector
kit V using a Nucleofector II device (Lonza, Preston, UK)
as per the manufacturer’s instructions, before plating at
1.6 × 10
4 cells/well in 12-well plates for transport assays
and immunofluorescence or 3.3 × 104 cells per 35mm dish
for luminometry. Plates and dishes were precoated with
0.1mg/mL poly-D-lysine.
2.5. [3H]E3S Transport Assay. Cells in 12-well plates at 72
hours after transfection were removed from the incubator
and the media were aspirated. Wells were washed three times
with 300 𝜇L uptake solution (142mMNaCl, 5mMKCl, 1mM
KH
2
PO
4
, 1.2mMMgSO
4
, 1.5mM CaCl
2
, 5mM glucose, and
12.5mM HEPES to pH 7.3), prewarmed to 37∘C. Cells were
then incubated in 300 𝜇L 0.1 𝜇M [3H]E3S plus 0–1.5 𝜇M
unlabeled substrate in uptake solution for 3min at 37∘C.
Transport was stopped by the addition of 300 𝜇L ice cold
uptake solution. Each well was washed a further three times
with ice cold uptake solution before the addition of 200𝜇L 1%
SDS/0.5MNaOH and shaken overnight at room temperature
to lyse the cells. For quantification 50 𝜇L cell/SDS/NaOH
solution was removed and 200𝜇L Optiphase Supermix
scintillation cocktail (Perkin Elmer, Witney UK) was added
before measuring in a Perkin Elmer 1450 Microbeta Trilux
liquid scintillation counter. The remaining solution was used
to quantify protein levels using the BCA protein assay kit
(Merck, Feltham UK). The [3H]E3S uptake was normalized
to the protein content in each well, to give transport in
pmol/mg protein/3min.
2.6. Kinetic Analysis. Kinetic parameters for transport of
[
3H]E3S by OATP1B1 were determined under initial rate
conditions. Transport of [3H]E3S was measured in the pres-
ence of unlabeled E3S (0–1.5𝜇M) and mediated transport
calculated by subtracting the uptake seen after transfection
with the empty vector. The Michaelis-Menten equation was
applied to obtain estimates of the maximal uptake rate (𝑉max)
and the apparent affinity constant (𝐾
𝑚
).
2.7. Luminometry Assay. The luminometry assaywas adapted
from the method described by Paavola et al. [43]. Cells in
35mm dishes at 72 hours after transfection were washed
and fixed with 1mL 4% paraformaldehyde. Cells were then
blocked with 1mL 2% dry nonfat milk in PBS for 30min,
before incubating with 1mL HRP-conjugated anti-FLAG
antibody (1 : 1000 in milk buffer) for 2 hours at room temper-
ature. Dishes were washed twice with milk buffer then once
with PBS before adding substrate (Pierce, Loughborough,
UK) and analysing in a TD-20/20 luminometer (Turner
Designs, Alton, UK). Luminometry readings were taken with
a 5-second delay and 30-second measurement. The cells
were lysed with 1mL of 1% SDS/0.5M NaOH and shaken
overnight at room temperature. Protein was quantified using
the BCA protein assay kit (Merck, Feltham, UK) to allow
normalization of the luminescence values (relative light units
(RLU) to the protein content (RLU/mg protein) in each dish.
2.8. Immunofluorescence and Confocal Microscopy.
HEK293T cells were grown on 15mm cover slips in 12-
well plates for 48 hours after transfection. Wells were washed
and cells were fixed by the addition of 4% paraformaldehyde,
4% sucrose for 15 minutes. Wells were washed with PBS
three times for 5 minutes per wash. After blocking with 10%
BSA in PBS for 30 minutes at 37∘C, cells were incubated with
primary monoclonal mouse anti-FLAG antibody (1 : 2000
in 5% BSA/PBS) for 2 hours at 37∘C. Wells were washed
with PBS three times/5min, followed by incubation with
anti-mouse IgG-fluorescein isothiocyanate (FITC) rabbit
secondary antibody (1 : 1000 in 5% BSA/PBS) for 45 minutes
at 37∘C. Wells were washed with PBS three times/5min.
Before mounting, wells were incubated with 1 𝜇g/mL 4󸀠,6-
diamidino-2-phenylindole (DAPI) for 2 minutes. Cover slips
were mounted face down over mounting media containing
1,4-diazabicyclo[2.2.2] octane (DABCO) on a standard glass
slide. Slides were visualized on the x40 lens of a Zeiss LSM
510 META confocal microscope. Images were acquired with
fixed settings to allow comparison between samples.
2.9. Statistical Analysis. Statistical significance of data was
calculated using a two-tailed unpaired Student’s 𝑡-test
(Graphpad Prism 5, CA USA) and statistical significance of
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Figure 1: Regions of the OATP1B1 protein predicted to be 𝛼-helical by PHYRE2 (x) [40], and the average positions of the TMs as predicted
by the algorithms that gave a 12-TMmodel (∼). The signature sequence is highlighted in yellow.
normalized data was calculated using a two-tailed one sample
𝑡-test (Sigmaplot 11.0, Systat Software, CA, USA), both with
𝑃 < 0.05 as significant.
3. Results
3.1. OATP1B1 Topology Results. A screen of all available topol-
ogy prediction programs was made to accurately predict the
topology of OATP1B1, to allow identification of an insertion
site for the FLAG eiptope. 16 programs were evaluated,
10 of which predicted OATP1B1 to contain 12 TMs with
intracellular N andC termini (TOPCONS, Phobius, TMpred,
TopPred II, Membrain, PHDhtm, Split 4.0, Philius, HMM-
TOP, and SVMtm). The remaining 6 programs predicted 11
TMs (ConPred II, SOSUI, TMHMM,TSeg, PRED-TMR, and
MEMSAT3), with TM4 from the 12-TMmodel not present in
the 11-TM model.
D S R W V G A W W L N F L
251 254
258 259 261
E F F F A
OATP1B1
sequence
Mutation
Figure 2: OATP1B1 signature sequence with amino acid positions
and mutations performed in this study. The region of the sequence
predicted to form part of TM 6 is highlighted in orange.
Homology modelling with the program PHYRE2 also
gave a 12-TM prediction based on GlpT [41], against which
65% of the OATP1B1 residues were modeled with >90%
confidence. The TM regions were consistent with those
predicted by the topology prediction software (Figure 1). The
software giving 12 TMs predicted the signature sequence to
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Extracellular
Intracellular
Signature sequence
FLAG epitope
Figure 3: Predicted 12-TM topology of OATP1B1 with intracellular N and C termini. The FLAG epitope was inserted into the extracellular
loop 2 between TMs 3 and 4 as directed by the topology predictions.The signature sequence is highlighted at the border between extracellular
loop 3 and TM 6.
span the extracellular loop 3 from D251-A257 and TM 6
from W258-L263 (Figure 2). The combined topology results
identified the putative extracellular loop between TMs 3 and
4 for the insertion of the FLAG epitope (Figure 3).
3.2. Functional Characterization of Wild Type OATP1B1
and Validation of OATP1B1-FLAG. Transport function of
OATP1B1 was quantified by measuring the uptake of the
radiolabeled substrate [3H]E3S into OATP1B1 transiently
transfected HEK293T cells. [3H]E3S uptake was linear up
to 5 minutes (Figure 4, inset); therefore kinetic experiments
were performed using a 3-minute uptake. Although biphasic
kinetics is associated with OATP1B1 [44, 45], only the high
affinity binding site was apparent under our experimental
conditions (0.1𝜇M [3H]E3S), with a 𝐾
𝑚
of 0.105 ± 0.008 𝜇M
and𝑉max of 50.1 ± 10.9 pmol/mg protein/3min (Figure 6(a)),
comparable to those found by other studies [46, 47].
3.3. Validation of the OATP1B1-FLAG Construct. Luminom-
etry experiments were performed to validate the extracel-
lularly located FLAG epitope on the OATP1B1 protein in
nonpermeabilized cells. A significant increase in lumines-
cence was observed in the OATP1B1-FLAG construct from
the wild type OATP1B1 (Figure 5(a)), confirming that the
FLAG epitope was placed in an extracellular portion of the
protein.
Transport experiments with [3H]E3S were conducted
to confirm that the OATP1B1-FLAG construct maintained
function following the addition of the epitope. [3H]E3S
uptake was measured alongside the OATP1B1 wild type
(Figure 5(b)). The OATP1B1-FLAG construct retained trans-
port function, with rates of uptake comparable to the
untagged (no epitope) OATP1B1. Transport kinetics were
performed with the OATP1B1-FLAG construct (Figure 6(b)),
86420
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Figure 4: Uptake of 0.1 𝜇M [3H]E3S at 37∘C between 0.5 and 10min
measured in HEK293T cells transiently transfected with OATP1B1-
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with a linear regression line.
producing a 𝐾
𝑚
of 0.159 ± 0.049 𝜇M and 𝑉max of 79.6 ±
6.5 pmol/mg protein/3min. There was no significant differ-
ence between the 𝐾
𝑚
values obtained for the FLAG-tagged
construct and the wild type transporter. The 𝑉max increased
compared to the wild type but not significantly.
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Prism).
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Figure 6: Uptake of increasing concentrations of 0.1𝜇M [3H]E3S + 0–1.5 𝜇M E3S was measured at 37∘C after 3min from (a) OATP1B1 and
(b) OATP1B1-FLAG transiently transfected HEK293T cells. The line is the Michaelis-Menten equation fitted to the 𝐾
𝑚
and 𝑉max. Each point
is the mean ± SE of 3 individual experiments with 3-well replicates and the pcDNA vector control uptake was subtracted.
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Figure 7: [3H]E3S uptake and luminometry results for OATP1B1-
FLAG control and D251E, W254F, W258/259F, and N261A mutant
constructs, transiently transfected into HEK293T cells. Uptake of
0.1 𝜇M [3H]E3S at 37∘C after 3minwasmeasured and pcDNAvector
control uptake was subtracted.TheOATP1B1-FLAG [3H]E3S uptake
was 15.4 pmol/mg protein/3min. Luminometry experiments were
measured as RLU/mg protein and OATP1B1 (no epitope) negative
control values were subtracted. Mutant values were normalized to
those of theOATP1B1-FLAGand expressed as a percentage. Each bar
is the mean ± SE of 3 experiments (luminometry = 3 dish replicates,
uptake = 6-well replicates). ∗Statistical decrease (𝑃 < 0.05) from the
OATP1B1-FLAG was determined by a two-tailed one sample 𝑡-test
(Sigmaplot 11.0).
3.4. Transport and Surface Expression of the OATP1B1-FLAG
Signature Sequence Mutants. Transport experiments were
conducted to elucidate whether the OATP1B1-FLAG signa-
ture sequence mutants maintained function following site-
directed mutagenesis. Uptake of [3H]E3S by the mutants
was measured alongside the OATP1B1-FLAG construct
(Figure 7).
Transport was significantly reduced from the OATP1B1-
FLAG forD251E,W254F, andW258/259Fmutants.Therewas
no significant difference in transport for N261A, nor were
the kinetic parameters changed from the OATP1B1-FLAG
(N261A 𝐾
𝑚
0.084 ± 0.033 𝜇M, 𝑉max 47.0 ± 19.4 pmol/mg
protein/3min). The low transport levels for the remaining
mutants meant that kinetic data could not be accurately
determined.
Luminometry was performed on the D251E, W254F,
W258/259F, and N261A signature sequence mutants to quan-
titatively measure surface expression in comparison to the
nonmutated OATP1B1-FLAG construct (Figure 7). Values
were normalized to those of the OATP1B1-FLAG to facilitate
the comparison. Surface expression was reduced significantly
compared to the nonmutated OATP1B1-FLAG for D251E,
W254F, and W258/259F. N261A surface expression was not
significantly different from the OATP1B1-FLAG.
Immunofluorescence experiments were performed to
further investigate protein localization and expression.
OATP1B1 expressing HEK293T cells were incubated with a
primary anti-FLAG and secondary-FITC conjugated anti-
body. The nucleic acid stain DAPI was also used to visualize
the cell nucleus. Figure 8 shows the confocal microscopy
images recorded from each mutant, for comparison with
the OATP1B1-FLAG positive control and OATP1B1 negative
control. The OATP1B1-FLAG control displayed predomi-
nantly membrane specific FITC fluorescence, as the N261A
mutant did. For the remaining mutants, D251E, W254F, and
W258/259F, the fluorescence was seen throughout the cell
rather than at the membrane.
4. Discussion
OATP1B1 is one of the most influential members of the
OATPs, owing to its role in the transport of many clinically
relevant compounds into the hepatocyte. The transporter is
central to the targeted drug delivery of statins [7], com-
plicated by the presence of approximately 40 SNPs in the
SLCO1B1 gene sequence [5]. It is likely that along with
other hepatic transporters and enzymes OATP1B1 plays an
important part in the ADME of compounds. Therefore this
particular transporter was apt for studying the structural
characteristics responsible for protein function and surface
expression.
OATP1B1 was predicted by 10 topology prediction pro-
grams and by GlpT homology modelling to contain 12 TMs
with intracellular N and C termini. This information allowed
the introduction of a FLAG epitope in extracellular loop 2
to facilitate the detection of surface expression. The 13 amino
acid signature sequence is present in all OATPs and is highly
conserved between species [4]. Its location at the interface
between extracellular loop 3 and TM 6 suggests a structural
role in protein folding and/or stability within the membrane.
Unfortunately this region of OATP1B1 is not represented in
the best PHYRE2 generated homology model, that with the
crystal structure of GlpT as the template, so site-directed
mutagenesis was used to investigate the role of conserved
residues in the signature sequence.
The highly conserved amino acids which form the sig-
nature sequence of OATP1B1 were found to be important
for surface expression. The introduction of D251E, W254F,
and W258/259F to OATP1B1 significantly reduced surface
expression and transport of [3H]E3S. Confocal microscopy
showed that protein was in fact produced but was predomi-
nantly retained in the cytoplasm, suggesting a role of D251,
W254, and W258/9 for protein folding and/or membrane
localization. These amino acids therefore are likely to have a
structural rather than functional role in the protein.
Tryptophan is a unique amino acid, exhibiting a large
nonpolar surface area, the capability for hydrogen bond
formation from the indole N–Hmoiety and the greatest elec-
trostatic potential for noncovalent interactions [23].Mutating
tryptophan to phenylalanine dramatically reduced transport
function, suggesting that the indole ringmay be an important
8 Journal of Drug Delivery
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Figure 8: Immunofluorescence of OATP1B1 negative control, OATP1B1-FLAG positive control, D251E, W254F, W258/259F, and N261A
transiently transfected HEK293T cells, visualized by confocal microscopy. DAPI (blue) localized to the nucleus (504 nm) and FITC (green)
localized to the FLAG epitope (488 nm). Scale bar = 20 𝜇M.
feature for hydrogen bonding and membrane stability in
OATP1B1 [20, 23]. In a previous study, individual mutation
of W258 and W259 to phenylalanine did not affect surface
expression [21]. Our results therefore suggest that at least
one tryptophan is required in this region of the protein, as
functional expression is not affected upon single mutation
of W258 or W259 to phenylalanine, but is abolished upon
the double mutation. However the double tryptophans in rat
OATP1C1 retained wild type characteristics when mutated to
phenylalanine [22], suggesting that different OATPs may be
able to function with the phenylalanine substitution.
The mutation of aspartic acid to glutamic acid (D251E)
significantly reduced transport and surface expression. As
both amino acids are negatively charged polar residues, it
may be that the extra methylene group in glutamic acid
disrupted protein folding. It has previously been reported that
aspartic acid may interact with tryptophan more frequently
than glutamic acid, following analysis of the spatial contacts
and solvent accessibility of the amino acids [48]. Therefore
it may also be that mutating to glutamic acid may have
changed the interactions with tryptophan, disrupting the
structure. D251E alongwithW254was predicted to form part
of the extracellular loop 3, a region of the signature structure
which has not previously been studied. N261A was the only
mutant to retain transport function and expression on the
membrane, supported by a previous study [21], suggesting
that the maintenance of a neutral charge is sufficient at this
position.
5. Conclusions
The amino acids D251, W254, and W258/9 within the signa-
ture sequence of OATP1B1 are important for protein surface
expression. Site-directed mutagenesis and topology predic-
tions are powerful tools for analyzing protein topology and
structural and functional roles of amino acids as currently
no mammalian drug transporters have been crystallized [21].
These results will contribute to the growing database of
structural and functional information on the OATPs and will
inform their role in drug delivery.
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